http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
말기신질환을 동반한 다발성 골수종 1예에서 시행된 자가말초혈액 조혈모세포이식
유승민,박정우,이규훈,방수미,안정열,박필환,조은경,신동복,이종호,이재훈 대한조혈모세포이식학회 2002 대한조혈모세포이식학회지 Vol.7 No.2
본 환자는 혈액투석이 요구되는 말기신질환을 동반한 다발성골수종으로 진단받고 VAD 유도요법으로 초기 치료 후 부분관해를 보였으며, melphalan 투여 후 자가말초 조혈모세포이식을 시행하여 심각한 부작용 없이 완전관해를 보이고 그 효과가 1년간 유지되어 이를 보고하는 바이다. Multiple myeloma with monoclonal gammopathy of the lambda light chain, which initially manifested as end-stage renal disease, was diagnosed in a 50-year-old man. Induction chemothery with VAD (vincristine, adriamycin, and dexamethasone) failed to induce a complete response. Complete remission was obtained after high-dose therapy using melphalan (100 mg/m²) followed by autologous peripheral stem cell transplantation. Hemodialysis was performed every day or every other day during induction and high- dose therapy. The adverse events during transplantation consisted of mucositis and neutropenic fever. This case demonstrated that a sustained complete response can be achieved in multiple myeloma complicated by end-stage renal failure using hemodialysis and high-dose chemotherapy without serious toxicity.
( Hye Jung Chang ),( Jae Hoon Lee ),( Young Rok Do ),( Sung Hwa Bae ),( Jung Lim Lee ),( Seung Hyun Nam ),( Sung Soo Yoon ),( Soo Mee Bang1 ) 대한내과학회 2011 The Korean Journal of Internal Medicine Vol.26 No.4
Background/Aims: The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a firstline treatment. Because the side effects of thalidomide at a dose of ≥ 100 mg daily can be a barrier to effective treatment for these patients, we evaluated the efficacy and safety of a reduced dose of thalidomide, 50 mg, for non-transplant candidates. Methods: Twenty-one patients were treated in 4-week cycles, receiving 4 mg/m2 melphalan and 40 mg/m2 prednisone on days 1-7 and 50 mg thalidomide daily. The primary efficacy outcome was the overall response rate. Aspirin (100 mg daily) was also provided as prophylactic treatment for thromboembolism. Results: The overall response rate was 57.1%; a complete response was seen in 23.8% of patients, a partial response in 33.3%, and stable disease in 9.5%. After a median follow-up time of 16.1 months, the median time to progression was 11.4 months (95% confidence interval, 2.1 to 20.6); the median overall survival was not reached. Grades 3 and 4 adverse events included infection (10%), peripheral neuropathy (5%), diarrhea (5%), thrombosis (10%), and loss of consciousness (10%). Two patients discontinued treatment due to loss of consciousness and neuropathy. Conclusions: Low-dose thalidomide (50 mg) plus melphalan and prednisone is an effective combination drug therapy option for newly diagnosed myeloma patients who are ineligible for high-dose chemotherapy.
Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
( Soo Mee Bang ),( Jeong Yeal Ahn ),( Ji Yoon Park ),( Soo Jin Yoo ),( Se Hoon Park ),( Eun Mi Nam ),( Pil Whan Park ),( Yiel Hea Seo ),( Eun Kyung Cho ),( Dong Bok Shin ),( Jae Hoon Lee ) 대한내과학회 2006 The Korean Journal of Internal Medicine Vol.21 No.4
Background: We investigated the Janus kinase 2 (JAK2) mutation and its diagnostic value in patients suffering with non BCR/ABL myeloproliferative diseases (nMPD) or other reactive conditions. Methods: We reviewed the clinical records of 83 patients who underwent bone marrow (BM) examinations with suspect of nMPD. The diagnoses of nMPD were made based on the WHO criteria since 2001 and the PVSG criteria before 2001. The JAK2 mutation was examined by PCR in 54 patients whose BM samples were available. Results: The JAK2 mutation was detected in 25 patients (46%); 12 of 26 patients with essential thrombocythemia (ET), 9 of 12 patients with polycyhtemia vera (PV), one of 7 patients with chronic idiopathic myelofibrosis (CIM) and one patient with unclassifiable MPD. Additionally, JAK2 mutation was detected in each one patient with secondary polycythemia and reactive thrombocytosis. These two patients and two other patients among the JAK2 mutated ET did not meet the WHO PV criteria due to their initial low hemoglobin levels. These patients had liver cirrhosis and hypersplenism due to Budd-Chiari syndrome (1), gastrointestinal bleeding (1) or the initial hemoglobin level was slightly below the level as provided by the criteria, but the level showed a rising pattern despite cytoreductive therapy (2). With the results of the JAK2 mutation available, 4 patients` disease could be re-diagnosed as PV. Finally, the positive rate of the JAK2 mutation was 81% in PV, 48% in ET and 14% in CIM. The presence of JAK2 mutation closely correlated with PV (p=0.001), leukocytosis (p=0.001) and an increased cellularity of BM (p=0.024). Conclusions: The JAK2 mutation may help differentiate nMPD from secondary cytosis. Therefore, it should be incorporated into the guidelines for the nMPD work-up for making a more accurate diagnosis and administering proper treatment.
Bang, Soo-Mee,Lee, Jeong-Ok,Kim, Yu Jung,Lee, Keun-Wook,Lim, Soo,Kim, Jee Hyun,Park, Young Joo,Chin, Ho Jun,Kim, Ki Woong,Jang, Hak-Chul,Lee, Jong Seok Springer International 2013 Annals of hematology Vol.92 No.1
<P>This study was planned to investigate the prevalence and risk factors of anemia and its impact on health-related quality of life and activities of daily living (ADL) in elderly Koreans. Of the 1,118 randomly sampled elderly Koreans aged 65?years or older living in Seongnam, Korea, on Aug. 1, 2005, we estimated the prevalence of anemia from 695 responders. We investigated the risk factors of anemia using a merged sample of this random sample and 270 volunteers enrolled from Seongnam residents aged 85?years or older. We diagnosed anemia according to the World Health Organization criteria. The estimated age- and gender-standardized prevalence of anemia was 8.33?% for the overall random sample (95?% confidence intervals (CI) 6.28-10.39), 10.58?% in men (95?% CI 7.09-14.07), and 6.85?% in women (95?% CI 4.37-9.34). The identified risk factors were age 80?years, male, iron deficiency, history of stroke, renal dysfunction, and metabolic syndrome. Anemia was associated with impairment in physical functioning (p?=?0.031) and instrumental ADL (p?<?0.001). This is the first report about anemia's prevalence in community-dwelling Korean elders, adjusted and standardized according to the city's and nation's population. Timely diagnosis of anemia and correction of its treatable cause may improve QOL and ADL in elderly individuals.</P>
Clinical Features of Waldenstrom Macroglobulinemia in Korea
( Soo Mee Bang ),( Sook Ryun Park ),( Se Hoon Park ),( Eun Kyung Cho ),( Sung Soo Yoon ),( Dong Bok Shin ),( Jae Hoon Lee ),( Seon Yang Park ),( Byoung Kook Kim ),( Noe Kyeong Kim ) 대한내과학회 2004 The Korean Journal of Internal Medicine Vol.19 No.3
Management of Coagulopathies in Liver Cirrhosis
( Soo Mee Bang ) 대한간학회 2015 간학회 싱글토픽 심포지움 Vol.2015 No.1
간경화 환자에서 새로 정립된 응고·항응고 재균형 개념은 환자의 출혈 및 혈전 위험도 평가, 출혈 시 대처 방안, 시술이나 수술을 대비하는 방법, 혈전 진단과 치료법 등에 대한 다양한 의문점과 해결해야 할 과제를 제시하였다. PT를 이용한 출혈위험도 평가는 정확하지 않으며 시술을 위해 신선동결혈장이나 혈소판 제제의 수혈은 자제하고 다른 출혈을 일으킬 수 있는 인자, 예를 들면 신부전이나 감염 등을 먼저 교정하는 것이 추천된다. 간문맥혈전의 유병률, 위험인자, 치료법 등에 대한 국내 연구가 필요하다.